P464 Rac1/pSTAT3 expression in T lymphocytes: A potential pharmacodynamic marker for thiopurines in the treatment of Inflammatory Bowel Disease patients?
Debbie S. Deben, Dennis R. Wong(Zuyderland Medisch Centrum), Arjan van Adrichem(Bravis Ziekenhuis), Mathie P.G. Leers(Zuyderland Medisch Centrum), A Van Bodegraven(Zuyderland Medisch Centrum), Roosmarie J.M. Drent(Zuyderland Medisch Centrum), Audrey H. H. Merry(Zuyderland Medisch Centrum), Rob H. Creemers(Zuyderland Medisch Centrum)
Cited by 0
Related Papers
Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study
|Journal of Crohn s and Colitis|2020|71
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
|Clinical Gastroenterology and Hepatology|2022|51
Therapeutic Drug Monitoring of Vedolizumab in Inflammatory Bowel Disease Patients during Maintenance Treatment—TUMMY Study
|Pharmaceutics|2023|17
Exposure to Thioguanine During 117 Pregnancies in Women With Inflammatory Bowel Disease
|Journal of Crohn s and Colitis|2022|16